Concomitant use of sorafenib with ombitasvir/paritaprevir/ritonavir and dasabuvir: Effectiveness and safety in clinical practice

Summary What is known and objective No studies have evaluated the use of sorafenib with the direct‐acting antiviral ombitasvir/paritaprevir/ritonavir and dasabuvir (OBV/PTV/r+DSV). Case summary Three hepatitis C virus genotype 1b‐infected patients with well‐preserved liver function were included in this prospective case series. The patients were taking sorafenib for advanced hepatocellular carcinoma and received OBV/PTV/r+DSV for 12 weeks. One patient discontinued sorafenib while concomitant treatment due to grade 2 fatigue and muscular pain. The other two patients reported only grade 1 adverse effects. Sustained virologic response at 24 weeks was achieved, and no tumour recurrences were found. What is new and conclusion The concurrent use of OBV/PTV/r+DSV with sorafenib was considered safe and effective. Metabolic and transporters profile